Bladder cancer is the fourth most common cancer in men and fifth most common overall. Despite improvements in chemotherapy, surgery and “personalized medicine” directed at tumor-specific mutations, the survival for bladder cancer is unchanged over the last 50 years. Patients with non-muscle invasive bladder cancer have a 70% risk of recurrence of their tumor at 5 years and those with muscle-invasive cancer have only a 50% survival 5 years after radical cystectomy and chemotherapy. Thus, there is an urgent need for novel therapies to improve treatment for patients with all stages of urothelial carcinoma.
|Effective start/end date||6/29/17 → 2/28/22|
- NextCure, Inc. (Agmt 6/29/17)